MNTN, Inc Class A (MNTN)
NYSE:MNTN
Want to see MNTN full AI Analyst Report?
Earnings Data
Report Date
Nov 10, 2026After Close (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
―Last Year’s EPS
0.08Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed solid top-line growth, expanding profitability, strong product adoption, and accelerated clinical trial progress — all meaningful positives. There are notable soft spots (a ~25% decline in MIS ablation, some international distributor weakness, modest sequential growth, and deliberate limits on SMB onboarding), but they appear manageable relative to the breadth of growth drivers and the company’s guidance for the year.Company Guidance
Strong Revenue Growth (Q1 2026)
Worldwide revenue of $141.2 million in Q1 2026, up 14.3% year-over-year (12.8% on a constant currency basis). U.S. revenue of $116.2 million, up 14.9% versus prior year; sequential revenue was roughly +1% versus Q4 2025.
Improved Profitability / Adjusted EBITDA
Reported adjusted EBITDA for the quarter of $17 million (nearly double Q1 of last year). Company also provided full-year adjusted EBITDA guidance of $96 million to $101 million.
Gross Margin Expansion
Gross margin improved materially: CFO reported 77.4% for 2026, up ~246 basis points versus 2025. Separately, management highlighted a quarter with an 81% gross margin driven by favorable revenue mix and cost actions (creative and hosting COGS benefits).
Rapid Clinical Trial Enrollment (BOX NOAF)
BOX NOAF randomized clinical trial has enrolled ~300 of 960 patients since enrollment began in Q4 last year and is tracking well ahead of plan; company now expects complete enrollment around the end of this year — nearly one year ahead of the original timeline.
Franchise-Level Growth — Pain Management
Pain management led portfolio growth with a 28% year-over-year increase; U.S. pain management sales were $22.4 million, up ~29.5% year-over-year. The Cryosphere/Cryo Max Pro device contributed roughly 70% of pain management sales in the quarter.
Franchise-Level Growth — Open Ablation & Appendage Management
Worldwide open ablation revenue grew ~15% in Q1 (U.S. open ablation sales +17.3% to $39.1 million). Worldwide appendage management grew ~16%, with U.S. appendage management sales of $48.4 million (+14.9%); AtriClip Flex Mini accounted for ~40% of open appendage management revenue in the U.S.
Regulatory and Product Launch Momentum
Received CE Mark under EU MDR for AtriClip Flex Mini and Pro Mini in Europe with launches expected later in the year. Multiple new product launches across the U.S., China, Japan and Europe were called out as growth drivers.
International Growth (Despite Headwinds)
International revenue totaled $25.0 million, up 11.5% on a reported basis and up 3.3% on a constant currency basis. European sales increased 13.2% ($16.1M) and Asia Pacific/other international sales rose 8.4% ($8.9M).
Forward Guidance Showing Back-Half Acceleration
Company provided Q2 revenue guidance of $81M–$83M (midpoint $82M, ~20% YoY growth) and full-year revenue guidance of $347M–$357M (midpoint ~24% YoY growth), indicating expected revenue acceleration in the back half.
Product Adoption and Competitive Differentiation
Management highlighted sustained adoption of Encompass clamp, strong take-up and share gains from AtriClip Flex Mini/Pro Mini, growing traction for Cryo XD therapy, and belief that differentiated innovation is driving market share gains.
MNTN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MNTN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $11.36 | $8.77 | -22.80% |
Feb 10, 2026 | $8.13 | $11.15 | +37.15% |
Nov 04, 2025 | $14.85 | $13.65 | -8.08% |
Aug 05, 2025 | $31.47 | $25.85 | -17.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MNTN, Inc Class A (MNTN) report earnings?
MNTN, Inc Class A (MNTN) is schdueled to report earning on Nov 10, 2026, After Close (Confirmed).
What is MNTN, Inc Class A (MNTN) earnings time?
MNTN, Inc Class A (MNTN) earnings time is at Nov 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MNTN EPS forecast?
Currently, no data Available